the Centers for Disease Control and Prevention (CDC) reported the first confirmed case of COVID-19 in the US. 1 Since then, in only 2.5 years, the global pandemic has resulted in 588 757 628 confirmed cases of and 6 433 794 deaths (as of August 8, 2022). 2 While the world is (once again) gradually reopening, the lingering social and economic effects of the pandemic are clearly felt, with national lockdowns and school closures still ongoing in 23 countries. Furthermore, the World Health Organization (WHO) recently forecasted a new wave of COVID-19, predicted to peak in the autumn and winter months, suggesting the potential need to reinstate disruptive measures in the northern hemisphere.Preparing for the future, the WHO released its autumn/ winter strategy for COVID-19, emphasizing the central role of diagnostics in counteracting the pandemic. Specifically, the organization recommended that countries should strengthen "laboratory capacities to ensure reliable rapid diagnostic SARS-CoV-2 detection and tracking of variants, complemented by continued population use of rapid diagnostic testing; [integrate] population-based surveillance systems for influenza, SARS-CoV-2 and other respiratory viruses to monitor the spread and intensity of respiratory viruses; [and prioritize] contact tracing and quarantining based on WHO recommendations for individuals, high-risk settings and situations of concern." 3 While reliable innovative diagnostic tests to detect SARS-CoV-2 were rapidly developed in the past 2 years, sampling has remained a major limiting factor, especially in settings where large-scale testing of symptomatic and asymptomatic populations are needed. The need for dedicated health care workers (HCWs), fitted with personal protective equipment, some of which has to be discarded between patients, has hampered implementation of mass screening. Sampling is time consuming, expensive, and exposes the HCW to potential transmission from patients. To address this barrier, several studies in adults have evaluated the use of self-collected samples for SARS-CoV-2 molecular testing and have demonstrated 93% to 97% concordance rates with standard swabs obtained by HCWs. [4][5][6][7] In this issue of JAMA, the study by Waggoner et al 8 further expands this knowledge by showing that school-aged children are capable of reliable selfsampling using nasal swabs.The authors enrolled children from kindergarten through eighth grade who were referred for SARS-CoV-2 testing due to symptoms compatible with COVID-19. The participants were shown a short instructional video demonstrating how to selfswab and were provided with an instructional pictorial hand-